中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2014年
7期
824-826
,共3页
王亮%马远征%张妍%陈立英%白颖%陈琼%陈烨%马伟凤%杨帆%谢媛媛%马彦巧%胡江伟%杨国花%王文娇
王亮%馬遠徵%張妍%陳立英%白穎%陳瓊%陳燁%馬偉鳳%楊帆%謝媛媛%馬彥巧%鬍江偉%楊國花%王文嬌
왕량%마원정%장연%진립영%백영%진경%진엽%마위봉%양범%사원원%마언교%호강위%양국화%왕문교
雷洛昔芬%骨密度%代谢%骨质疏松%绝经后妇女
雷洛昔芬%骨密度%代謝%骨質疏鬆%絕經後婦女
뢰락석분%골밀도%대사%골질소송%절경후부녀
Raloxifene HCL%Bone mineral density%Metabolism%Osteoporosis%Postmenopausal women
目的：研究盐酸雷洛昔芬（Raloxifene HCL，RLX）治疗绝经后骨质疏松妇女临床疗效，骨密度、血生化指标及血脂的影响。方法选择2010年1月－2013年1月在我科住院绝经后骨质疏松患者共90例，每人每天服用元素钙600 mg，活性维生素D 0．5μg作为基本补充剂，每日服用盐酸雷洛昔芬60 mg，共治疗12个月。观察指标为：腰椎、髋部骨密度；骨标志物、血生化指标。骨密度测定采用双能X线吸收法，骨标志物测定采用酶联免疫吸附法，血生化检测应用酶法。结果研究结束时，腰椎骨密度0．848±0．167，Ward三角骨密度0．536±0．126，较治疗前0．842±0．181、0．500±0．112均有显著提高，差异具有统计学意义；治疗后，血清CTX、BGP均较治疗前显著降低，而PTH较治疗前升高；治疗前后两组血脂水平无显著差异。结论盐酸雷洛昔芬能够显著增加绝经后骨质疏松妇女腰椎和髋部的骨密度，显著降低骨转换率，对绝经后妇女骨质疏松治疗效果较好。
目的：研究鹽痠雷洛昔芬（Raloxifene HCL，RLX）治療絕經後骨質疏鬆婦女臨床療效，骨密度、血生化指標及血脂的影響。方法選擇2010年1月－2013年1月在我科住院絕經後骨質疏鬆患者共90例，每人每天服用元素鈣600 mg，活性維生素D 0．5μg作為基本補充劑，每日服用鹽痠雷洛昔芬60 mg，共治療12箇月。觀察指標為：腰椎、髖部骨密度；骨標誌物、血生化指標。骨密度測定採用雙能X線吸收法，骨標誌物測定採用酶聯免疫吸附法，血生化檢測應用酶法。結果研究結束時，腰椎骨密度0．848±0．167，Ward三角骨密度0．536±0．126，較治療前0．842±0．181、0．500±0．112均有顯著提高，差異具有統計學意義；治療後，血清CTX、BGP均較治療前顯著降低，而PTH較治療前升高；治療前後兩組血脂水平無顯著差異。結論鹽痠雷洛昔芬能夠顯著增加絕經後骨質疏鬆婦女腰椎和髖部的骨密度，顯著降低骨轉換率，對絕經後婦女骨質疏鬆治療效果較好。
목적：연구염산뢰락석분（Raloxifene HCL，RLX）치료절경후골질소송부녀림상료효，골밀도、혈생화지표급혈지적영향。방법선택2010년1월－2013년1월재아과주원절경후골질소송환자공90례，매인매천복용원소개600 mg，활성유생소D 0．5μg작위기본보충제，매일복용염산뢰락석분60 mg，공치료12개월。관찰지표위：요추、관부골밀도；골표지물、혈생화지표。골밀도측정채용쌍능X선흡수법，골표지물측정채용매련면역흡부법，혈생화검측응용매법。결과연구결속시，요추골밀도0．848±0．167，Ward삼각골밀도0．536±0．126，교치료전0．842±0．181、0．500±0．112균유현저제고，차이구유통계학의의；치료후，혈청CTX、BGP균교치료전현저강저，이PTH교치료전승고；치료전후량조혈지수평무현저차이。결론염산뢰락석분능구현저증가절경후골질소송부녀요추화관부적골밀도，현저강저골전환솔，대절경후부녀골질소송치료효과교호。
Objective To investigate the effect of raloxifene HCL ( RLX) on serum biochemistry, bone markers, and bone mineral density ( BMD ) in women with postmenopausal osteoporosis.Methods A total of 90 patients with postmenopausal osteoporosis, who were hospitalized in our department from January 2010 to January 2010, were selected.All the patients took 600 mg calcium and 0.5μg active vitamin D every day as the basic supplements.The patients also took 60 mg RLX every week for 12 months.The obvervational indexes included BMD of the lumbar vertebrae and the hip, bone markers, and serum biochemical indexes.BMD was detected using dual-energy X-ray absorptiometry. Bone markers were determined using enzyme-linked immunosorbent method.Serum biochemical indexes were detected using enzymic method.Results BMD of the lumbar vertebrae and the Ward’ s triangle was 0.848 ±0.167 and 0.536 ±0.126, respectively, which was higher than that before the treatment (0.842 ±0.181 and 0.500 ±0.112, respectively), and the difference was statistically significant (P<0.05).The serum levels of CTX and BGP decreased significantly than those before the treatment, while the serum PTH level was higher than that before the treatment.No significant difference of the serum levels of blood lipids between two groups was observed.Conclusion Raloxifene hydrochloride increases BMD of the lumbar vertebrae and the hip in women with postmenopausal osteoporosis, and reduces the bone turnover significantly.So, it has good therapeutic effect for postmenopausal osteoporosis.
